Esperion Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ESPR and other ETFs, options, and stocks.

About ESPR

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. 

CEO
Sheldon L. Koenig
CEOSheldon L. Koenig
Employees
294
Employees294
Headquarters
Ann Arbor, Michigan
HeadquartersAnn Arbor, Michigan
Founded
1998
Founded1998
Employees
294
Employees294

ESPR Key Statistics

Market cap
643.31M
Market cap643.31M
Price-Earnings ratio
-12.94
Price-Earnings ratio-12.94
Dividend yield
Dividend yield
Average volume
6.63M
Average volume6.63M
High today
$2.71
High today$2.71
Low today
$2.51
Low today$2.51
Open price
$2.67
Open price$2.67
Volume
1.26M
Volume1.26M
52 Week high
$4.18
52 Week high$4.18
52 Week low
$0.6925
52 Week low$0.6925

Stock Snapshot

Esperion Therapeutics(ESPR) stock is priced at $2.51, giving the company a market capitalization of 643.31M. It carries a P/E multiple of -12.94.

During the trading session on 2026-03-18, Esperion Therapeutics(ESPR) shares reached a daily high of $2.71 and a low of $2.51. At a current price of $2.51, the stock is 0.0% higher than the low and still -7.6% under the high.

Trading activity shows a volume of 1.26M, compared to an average daily volume of 6.63M.

Over the past 52 weeks, Esperion Therapeutics(ESPR) stock has traded between a high of $4.18 and a low of $0.69.

Over the past 52 weeks, Esperion Therapeutics(ESPR) stock has traded between a high of $4.18 and a low of $0.69.

ESPR News

TipRanks 5d
Esperion price target raised to $5 from $4 at Citizens

Citizens raised the firm’s price target on Esperion (ESPR) to $5 from $4 and keeps an Outperform rating on the shares. Esperion reported Q4 results consistent w...

TipRanks 6d
Esperion Therapeutics Flags Material Weakness in Financial Controls, Raising Reporting and Regulatory Risks

Esperion Therapeutics (ESPR) has disclosed a new risk, in the Accounting & Financial Operations category. Esperion Therapeutics faces heightened reporting risk...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

People also own

Based on the portfolios of people who own ESPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.